BerGenBio ASA: Annual general meeting held
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Bergen 22 May 2023. Reference is made to the stock exchange announcements published by BerGenBio ASA (the "Company") on 25 April 2023 and 20 May 2023 regarding a proposed partially underwritten rights issue of shares with preferential rights for existing shareholders in the Company (the "Rights Issue").
The annual general meeting of the Company has today, on 22 May 2023, approved all items as proposed by the Board of Directors including the Rights Issue and the issuance of warrants. The minutes from the annual general meeting are enclosed hereto and will also be available on the Company’s website, in the Investor/General meeting section.
The full terms and conditions for the Rights Issue will be included in a prospectus, which will be published prior to the commencement of the subscription period for the Rights Issue. The subscription period is expected to take place from 30 May 2023 09:00 hours (CEST) to 13 June 2023 at 16.30 (CEST).
Carnegie AS and Arctic Securities AS are acting as managers (the "Managers") in the Rights Issue. Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in connection with the Rights Issue.
For further information, please contact:
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
Investor Relations / Media Relations
Graham Morrell
For information about the Rights Issue please contact the Managers:
Arctic Securities AS, tel.: + 47 21 01 30 40
Carnegie AS, tel.: +47 22 00 93 40
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.